The role of targeted therapy in ovarian cancer
The role of targeted therapy in ovarian cancer
复制标题
DOI：
10.1016/s0959-8049(11)70155-1
复制
发表时间：
2011-09-01
影响因子：
8.4
通讯作者：
Kaye, Stan
中科院分区：
文献类型：
--
作者：
Banerjee, Susana;Kaye, Stan
卵巢癌是第二常见的妇科恶性肿瘤，也是妇科癌症死亡的主要原因。虽然在某些情况下，治疗最初是有效的，但疾病复发和对治疗产生抗药性的风险相当大。靶向肿瘤分子改变的疗法提供了显著改善治疗的希望。目前最有希望的靶向药物是血管生成抑制剂和PARP抑制剂。在这里，我们回顾了卵巢癌I期和II期临床研究中的各种靶向治疗方法，以及它们在临床上未来成功所面临的挑战。
Ovarian cancer is the second most common gynaecological malignancy and the leading cause of death from gynaecological cancer. Although in some cases treatment is initially effective, there is a considerable risk of disease recurrence and resistance to therapy. Therapies targeting molecular alterations in tumours offer the promise of significantly improved treatment. So far, the most promising targeted agents are angiogenesis inhibitors and PARP inhibitors. Here, we review the various targeted therapeutic approaches under clinical investigation in phase I and II trials of ovarian cancer and the challenges facing their future success in the clinic.